Literature DB >> 25970242

MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis.

Cheryl M Koh1, Marco Bezzi2, Diana H P Low1, Wei Xia Ang1, Shun Xie Teo1, Florence P H Gay1, Muthafar Al-Haddawi1, Soo Yong Tan1, Motomi Osato3, Arianna Sabò4, Bruno Amati5, Keng Boon Wee6, Ernesto Guccione7.   

Abstract

Deregulated expression of the MYC transcription factor occurs in most human cancers and correlates with high proliferation, reprogrammed cellular metabolism and poor prognosis. Overexpressed MYC binds to virtually all active promoters within a cell, although with different binding affinities, and modulates the expression of distinct subsets of genes. However, the critical effectors of MYC in tumorigenesis remain largely unknown. Here we show that during lymphomagenesis in Eµ-myc transgenic mice, MYC directly upregulates the transcription of the core small nuclear ribonucleoprotein particle assembly genes, including Prmt5, an arginine methyltransferase that methylates Sm proteins. This coordinated regulatory effect is critical for the core biogenesis of small nuclear ribonucleoprotein particles, effective pre-messenger-RNA splicing, cell survival and proliferation. Our results demonstrate that MYC maintains the splicing fidelity of exons with a weak 5' donor site. Additionally, we identify pre-messenger-RNAs that are particularly sensitive to the perturbation of the MYC-PRMT5 axis, resulting in either intron retention (for example, Dvl1) or exon skipping (for example, Atr, Ep400). Using antisense oligonucleotides, we demonstrate the contribution of these splicing defects to the anti-proliferative/apoptotic phenotype observed in PRMT5-depleted Eµ-myc B cells. We conclude that, in addition to its well-documented oncogenic functions in transcription and translation, MYC also safeguards proper pre-messenger-RNA splicing as an essential step in lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25970242     DOI: 10.1038/nature14351

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  32 in total

1.  MYC recruits the TIP60 histone acetyltransferase complex to chromatin.

Authors:  Scott R Frank; Tiziana Parisi; Stefan Taubert; Paula Fernandez; Miriam Fuchs; Ho-Man Chan; David M Livingston; Bruno Amati
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

2.  Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors.

Authors:  Matilde Murga; Stefano Campaner; Andres J Lopez-Contreras; Luis I Toledo; Rebeca Soria; Maria F Montaña; Luana D' Artista; Thomas Schleker; Carmen Guerra; Elena Garcia; Mariano Barbacid; Manuel Hidalgo; Bruno Amati; Oscar Fernandez-Capetillo
Journal:  Nat Struct Mol Biol       Date:  2011-11-27       Impact factor: 15.369

3.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

4.  Emerging Concepts in the Analysis of Transcriptional Targets of the MYC Oncoprotein: Are the Targets Targetable?

Authors:  Chi Van Dang; Steven B McMahon
Journal:  Genes Cancer       Date:  2010-06

5.  A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.

Authors:  Zacharias Aloysius Dwi Pramono; Keng Boon Wee; Jian Li Wang; Yi Jun Chen; Qian Bin Xiong; Poh San Lai; Woon Chee Yee
Journal:  Hum Gene Ther       Date:  2012-07-13       Impact factor: 5.695

6.  Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues.

Authors:  Dorothe Hameyer; Ate Loonstra; Leonid Eshkind; Steffen Schmitt; Cecilia Antunes; Annemiek Groen; Eric Bindels; Jos Jonkers; Paul Krimpenfort; Ralph Meuwissen; Loes Rijswijk; Axel Bex; Anton Berns; Ernesto Bockamp
Journal:  Physiol Genomics       Date:  2007-04-24       Impact factor: 3.107

Review 7.  The spliceosome as a target of novel antitumour drugs.

Authors:  Sophie Bonnal; Luisa Vigevani; Juan Valcárcel
Journal:  Nat Rev Drug Discov       Date:  2012-11       Impact factor: 84.694

8.  The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation.

Authors:  Olga Anczuków; Avi Z Rosenberg; Martin Akerman; Shipra Das; Lixing Zhan; Rotem Karni; Senthil K Muthuswamy; Adrian R Krainer
Journal:  Nat Struct Mol Biol       Date:  2012-01-15       Impact factor: 15.369

9.  Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency.

Authors:  Maria Barna; Aya Pusic; Ornella Zollo; Maria Costa; Nadya Kondrashov; Eduardo Rego; Pulivarthi H Rao; Davide Ruggero
Journal:  Nature       Date:  2008-11-16       Impact factor: 49.962

10.  The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells.

Authors:  A W Harris; C A Pinkert; M Crawford; W Y Langdon; R L Brinster; J M Adams
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  149 in total

Review 1.  MYC: connecting selective transcriptional control to global RNA production.

Authors:  Theresia R Kress; Arianna Sabò; Bruno Amati
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

2.  PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.

Authors:  Lindsay M Webb; Stephanie A Amici; Kyle A Jablonski; Himanshu Savardekar; Amanda R Panfil; Linsen Li; Wei Zhou; Kevin Peine; Vrajesh Karkhanis; Eric M Bachelder; Kristy M Ainslie; Patrick L Green; Chenglong Li; Robert A Baiocchi; Mireia Guerau-de-Arellano
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 3.  PRMT7 as a unique member of the protein arginine methyltransferase family: A review.

Authors:  Kanishk Jain; Steven G Clarke
Journal:  Arch Biochem Biophys       Date:  2019-02-22       Impact factor: 4.013

Review 4.  Altered RNA Processing in Cancer Pathogenesis and Therapy.

Authors:  Esther A Obeng; Connor Stewart; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-10-14       Impact factor: 39.397

5.  MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.

Authors:  Gregory V Kryukov; Frederick H Wilson; Jason R Ruth; Joshiawa Paulk; Aviad Tsherniak; Sara E Marlow; Francisca Vazquez; Barbara A Weir; Mark E Fitzgerald; Minoru Tanaka; Craig M Bielski; Justin M Scott; Courtney Dennis; Glenn S Cowley; Jesse S Boehm; David E Root; Todd R Golub; Clary B Clish; James E Bradner; William C Hahn; Levi A Garraway
Journal:  Science       Date:  2016-02-11       Impact factor: 47.728

Review 6.  Environmental influences on RNA processing: Biochemical, molecular and genetic regulators of cellular response.

Authors:  Athma A Pai; Francesca Luca
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-09-14       Impact factor: 9.957

7.  Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors.

Authors:  Pia Riemke; Melinda Czeh; Josephine Fischer; Carolin Walter; Saeed Ghani; Matthias Zepper; Konstantin Agelopoulos; Stephanie Lettermann; Marie L Gebhardt; Nancy Mah; Andre Weilemann; Michael Grau; Verena Gröning; Torsten Haferlach; Dido Lenze; Ruud Delwel; Marco Prinz; Miguel A Andrade-Navarro; Georg Lenz; Martin Dugas; Carsten Müller-Tidow; Frank Rosenbauer
Journal:  EMBO J       Date:  2016-08-29       Impact factor: 11.598

8.  Aberrant RNA Splicing in Cancer.

Authors:  Luisa Escobar-Hoyos; Katherine Knorr; Omar Abdel-Wahab
Journal:  Annu Rev Cancer Biol       Date:  2018-11-28

Review 9.  Splicing factor gene mutations in hematologic malignancies.

Authors:  Borja Saez; Matthew J Walter; Timothy A Graubert
Journal:  Blood       Date:  2016-12-09       Impact factor: 22.113

10.  The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5.

Authors:  Huan-Tian Zhang; Ling-Fei Zeng; Qing-Yu He; W Andy Tao; Zhen-Gang Zha; Chang-Deng Hu
Journal:  Biochim Biophys Acta       Date:  2015-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.